Search research articles
Contact Us
Filters
Showing results (51-60 of 108) with videos related to
Page
of 11
Sort By:
Blood
|
May 28, 2017
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
Vaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 16, 2023
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study
Myo Htut, Binod Dhakal, Adam D Cohen, et al.
Cancer
|
August 18, 2017
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma
Jatin J Shah, Jonathan L Kaufman, Jeffrey A Zonder, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 29, 2014
Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee
Noopur Raje, Beth Faiman, R Donald Harvey, et al.
The Journal of Experimental Medicine
|
May 5, 2026
Rab5 improves CAR T cell efficacy via reducing fratricide and maintaining surface CAR levels
Meidi Gu, Kaitlin A Read, Vipin Bhardwaj, et al.
Blood Cancer Journal
|
October 24, 2020
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study
Paul G Richardson, Hans C Lee, Al-Ola Abdallah, et al.
Blood
|
September 25, 2024
Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma
Holly Lee, Michael Durante, Sheri Skerget, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 12, 2016
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma
Noopur S Raje, Edward A Faber, Paul G Richardson, et al.
Cancer Immunology Research
|
February 13, 2019
Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine-Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma
Adam D Cohen, Nikoletta Lendvai, Sarah Nataraj, et al.
Blood Cancer Discovery
|
August 26, 2022
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma
Kavita M Dhodapkar, Adam D Cohen, Akhilesh Kaushal, et al.
Page
of 11
Search research articles
Search
Showing results (51-60 of 108) with videos related to
Sort By:
Page
of 11
Blood
|
May 28, 2017
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
Vaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 16, 2023
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study
Myo Htut, Binod Dhakal, Adam D Cohen, et al.
Cancer
|
August 18, 2017
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma
Jatin J Shah, Jonathan L Kaufman, Jeffrey A Zonder, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 29, 2014
Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee
Noopur Raje, Beth Faiman, R Donald Harvey, et al.
The Journal of Experimental Medicine
|
May 5, 2026
Rab5 improves CAR T cell efficacy via reducing fratricide and maintaining surface CAR levels
Meidi Gu, Kaitlin A Read, Vipin Bhardwaj, et al.
Blood Cancer Journal
|
October 24, 2020
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study
Paul G Richardson, Hans C Lee, Al-Ola Abdallah, et al.
Blood
|
September 25, 2024
Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma
Holly Lee, Michael Durante, Sheri Skerget, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 12, 2016
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma
Noopur S Raje, Edward A Faber, Paul G Richardson, et al.
Cancer Immunology Research
|
February 13, 2019
Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine-Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma
Adam D Cohen, Nikoletta Lendvai, Sarah Nataraj, et al.
Blood Cancer Discovery
|
August 26, 2022
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma
Kavita M Dhodapkar, Adam D Cohen, Akhilesh Kaushal, et al.
Page
of 11